BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33549503)

  • 1. Consistency of chronic obstructive pulmonary disease regimens for patients visiting community pharmacies with the Global Initiative for Chronic Obstructive Lung Disease recommendations.
    Prosser TR; Bollmeier SG
    J Am Pharm Assoc (2003); 2021; 61(3):299-307. PubMed ID: 33549503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance between reported medication taking behavior and prescription instructions for patients with chronic obstructive pulmonary disease visiting community pharmacies.
    Prosser TR; Bollmeier SG
    J Am Pharm Assoc (2003); 2022; 62(4):1280-1286. PubMed ID: 35277361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting.
    Bollmeier SG; Seaton TL; Prosser TR; Chou YT; Reckenberg K; Hahn B; Stanford RH; Ray R
    J Am Pharm Assoc (2003); 2019; 59(4):479-488.e1. PubMed ID: 31126830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Medication Regimen Complexity of COPD Regimens in Individuals Visiting Community Pharmacies.
    Prosser TR; Bollmeier SG
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1499-1510. PubMed ID: 37489240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.
    Ghosh S; Anderson WH; Putcha N; Han MK; Curtis JL; Criner GJ; Dransfield MT; Barr RG; Krishnan JA; Lazarus SC; Cooper CB; Paine R; Peters SP; Hansel NN; Martinez FJ; Drummond MB;
    Ann Am Thorac Soc; 2019 Feb; 16(2):200-208. PubMed ID: 30216731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacy-Based eHealth Intervention Promoting Correct Use of Medication in Patients With Asthma and COPD: Nonrandomized Pre-Post Study.
    Schnoor K; Versluis A; Bakema R; van Luenen S; Kooij MJ; van den Heuvel JM; Teichert M; Honkoop PJ; van Boven JFM; Chavannes NH; Aardoom JJ
    J Med Internet Res; 2022 Jun; 24(6):e32396. PubMed ID: 35675120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
    Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
    Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients.
    Contoli M; Campo G; Pavasini R; Marchi I; Pauletti A; Balla C; Spanevello A; Ferrari R; Papi A
    Eur J Intern Med; 2018 Jan; 47():82-86. PubMed ID: 28821412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
    Price D; Miravitlles M; Pavord I; Thomas M; Wedzicha J; Haughney J; Bichel K; West D
    NPJ Prim Care Respir Med; 2016 Nov; 26():16061. PubMed ID: 27808096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of early medication use for COPD: a population-based cohort study.
    Falk J; Dik N; Bugden S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study.
    Hsieh MJ; Huang SY; Yang TM; Tao CW; Cheng SL; Lee CH; Kuo PH; Wu YK; Chen NH; Hsu WH; Hsu JY; Lin MS; Wang CC; Wei YF; Tsai YH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2949-2959. PubMed ID: 30310271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort.
    Wei YF; Kuo PH; Tsai YH; Tao CW; Cheng SL; Lee CH; Wu YK; Chen NH; Hsu WH; Hsu JY; Lin MS; Wang CC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1951-6. PubMed ID: 26392770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts.
    Lee SH; Lee JH; Yoon HI; Park HY; Kim TH; Yoo KH; Oh YM; Jung KS; Lee SD; Lee SW
    Respir Res; 2019 Mar; 20(1):62. PubMed ID: 30922302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.